WoundReference improves clinical decisions
 Choose the role that best describes you
Waycaster C, Carter MJ, Gilligan AM, Mearns ES, Fife CE, Milne CT, et al.
Journal of comparative effectiveness research. Date of publication 2017 Oct 27;volume ():.
1. J Comp Eff Res. 2017 Oct 27. doi: 10.2217/cer-2017-0066. [Epub ahead of print] Comparative cost and clinical effectiveness of clostridial collagenase ointment for chronic dermal ulcers. Waycaster C(1), Carter MJ(2), Gilligan AM(3), Mearns ES(4), Fife CE(5), Milne CT(6). Author information: (1)Smith & Nephew, Fort Worth, TX 76109, USA. (2)Strategic Solutions, Inc., Cody, WY 82414, USA. (3)Truven Health Analytics, Houston, TX 77056, USA. (4)Truven Health Analytics, an IBM Company, Cambridge, MA 02140, USA. (5)Baylor College of Medicine, Houston, TX 77030, USA. (6)Connecticut Clinical Nursing Associates, LLC, Bristol, CT 06011, USA. Chronic dermal ulcers affect approximately 2.4-4.5 million people in the USA and are associated with loss of function, decreased quality of life and significant economic burden. Debridement is a critical component of wound care involving removal of nonviable tissue from chronic wounds to stimulate the granulation and epithelialization process. Clostridial collagenase ointment has been used as a method of wound debridement for more than 50 years and is currently the only enzymatic debriding ointment with US FDA approval. This review discusses the results of recent real-world studies that build upon the evidence demonstrating the clinical effectiveness, cost-effectiveness and safety of clostridial collagenase ointment across wound types and care settings. DOI: 10.2217/cer-2017-0066 PMID: 29076747
Appears in following Topics:
Debridement: Enzymatic